DeepMed Research

AB598

Generic Name: AB598

Clinical Trials

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Phase 1

Recruiting

Conditions: Bladder Cancer
Advanced Malignancies
Head and Neck Squamous Cell Carcinoma (HNSCC)
Advanced Cancer
Esophageal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer (NSCLC)
Ovarian Cancer
Renal Cell Carcinoma (RCC)
Triple Negative Breast Cancer (TNBC)

Interventions: Drug: AB598
Drug: Zimberelimab
Drug: Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin

First Posted Date: 2023-06-06

Last Posted Date: 2025-04-29

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 87

Registration Number: NCT05891171

Locations: 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸
Ronald Reagan UCLA Medical Center, Santa Monica, California, United States

and more 17 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy